APA (7. basım) Alıntı

Vallis, K., Reilley, R., Scollard, D., Petronis, J., Caldwell, C., Hendler, A., . . . Oza, A. (2005). A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer.

Chicago Style (17. basım) Atıf

Vallis, K., R. Reilley, D. Scollard, J. Petronis, C. Caldwell, A. Hendler, G. Lockwood, ve A. Oza. A Phase I Clinical Trial to Evaluate the Pharmacokinetics, Toxicity and Dosimetry of 111-indium-labeled Human Epidermal Growth Factor in Patients with Metastatic Breast Cancer. 2005.

MLA (9th ed.) Atıf

Vallis, K., et al. A Phase I Clinical Trial to Evaluate the Pharmacokinetics, Toxicity and Dosimetry of 111-indium-labeled Human Epidermal Growth Factor in Patients with Metastatic Breast Cancer. 2005.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..